Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | GRPR | P30550 | 18/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurokinin B SCHEMBL29440672 | 0.83 | GRPR (0.59) | GRPR | |
| Neurokinin B SCHEMBL29390479 | 0.83 | GRPR (0.59) | GRPR | |
| SCHEMBL30350156 | 0.78 | TACR3 (0.57) | GRPR | |
| Neurokinin A SCHEMBL29374084 | 0.77 | PTH1R (0.62) | — | |
| Neurokinin A SCHEMBL29374005 | 0.77 | PTH1R (0.62) | — | |
| SCHEMBL31332118 | 0.75 | AGTR2 (0.71) | — | |
| SCHEMBL14364816 | 0.74 | GRPR (0.58) | GRPR | |
| SCHEMBL14364824 | 0.74 | GRPR (0.62) | GRPR | |
| SCHEMBL29406603 | 0.74 | CTSB (0.54) | — | |
| SCHEMBL13781414 | 0.74 | GRPR (0.57) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | AKT1 748/4885GRPR 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.